Humana Inc (HUM) Earnings: FY Adjusted EPS Forecast Steady at $16.00 Despite Market Estimates

Humana Inc on Smartkarma

In Humana Inc.’s recent coverage on Smartkarma by Baptista Research, the research report titled “Humana Inc.: Impacts on Pharmacy Benefit Managers (PBMs) Resulting From IRA Changes & Other Major Drivers” provides a bullish outlook on the company. The report discusses Humana, a leading health insurance provider, and its first quarter results for 2024. CEO Bruce Broussard and CFO Susan Diamond shared insights during a Q&A session post-earnings call, emphasizing the company’s solid start to the year. Humana reaffirmed its full-year adjusted earnings per share (EPS) guidance at around $16 and increased its individual Medicare Advantage (MA) membership growth outlook.

A look at Humana Inc Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Humana Inc. is positioned for a solid long-term outlook based on its Smartkarma Smart Scores analysis. With a strong momentum score of 4, the company is showing positive trends in its stock price that are likely to continue. This indicates a good potential for growth and performance in the future. Additionally, Humana scores well in value, growth, and resilience, with scores of 3 across these factors. This shows that the company is fundamentally strong and has the potential to provide good returns to investors over the long term.

While the dividend score is slightly lower at 2, the overall outlook for Humana Inc. remains positive. As a managed healthcare company serving members in the US and Puerto Rico, Humana offers a range of health care products to various customer segments. Its strong performance across key factors positions it well for sustained success in the evolving healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma